Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models

Cancer Immunology, Immunotherapy

Volumn 62, Issue 9, 2013, Pages 1533-1545

  Jure Kunkel, Maria ^a   Masters, Gregg ^a   Girit, Emel ^a   Dito, Gennaro ^a   Lee, Francis ^a   Hunt, John T ^a   Humphrey, Rachel ^b,c  

^a BRISTOL MYERS SQUIBB   (United States)

^b METHYLGENE INC   (Canada)

^c MethylGene US   (United States)

Author keywords

Chemotherapy; CTLA 4; Preclinical; Synergy; Tumor model

Indexed keywords

ETOPOSIDE; GEMCITABINE; IPILIMUMAB; IXABEPILONE; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL EXPANSION; COHORT ANALYSIS; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; FIBROSARCOMA; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CARCINOMA; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DEOXYCYTIDINE; DRUG SYNERGISM; EPOTHILONES; ETOPOSIDE; FEMALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL;

EID: 84883450601     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1451-5     Document Type: Article

References (42)

1. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immuno 6:715-727
2. Whiteside TL (2010) Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10:1019-1035
3. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339
4. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:95-106
5. Sharpe AH (2009) Mechanisms of co-stimulation. Immunol Rev 229:5-11
6. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
7. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793-801
8. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465
9. Krummel MF, Sullivan TJ, Allison JP (1996) Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T-cell expansion in vitro and in vivo. Int Immunol 8:519-523
10. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540
11. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP (1996) The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-46
12. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271-275
13. Rudd CE, Taylor A, Schneider H (2009) CD28 and CTLA-4 co-receptor expression and signal transduction. Immunol Rev 229:12-26
14. Yokosuka T, Kobayashi W, Takamatsu M, Sakata-Sogawa K, Zeng H, Hashimoto-Tane A, Yagita H, Tokunaga M, Saito T (2010) Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 33:326-339
15. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600-603
16. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988
17. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547
18. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA-4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213
19. Korman A, Yellin M, Keler T (2005) Tumor immunotherapy: preclinical and clinical activity of anti-CTLA-4 antibodies. Curr Opin Investig Drugs 6:582-591
20. Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-5283
21. Grosso JF, Jure-Kunkel MN (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 13:5
22. US YERVOY™ (2011) (ipilimumab) [package insert]. Bristol-Myers Squibb Company, Princeton
23. Ribas A, Hanson DC, Noe DA (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12:873-883
24. Hodi FS, O'Day SJ, McDermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
25. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372
26. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhaqui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968-8977
27. Robert C, Thomas L, Bondarenko I (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
28. Nowak A, Robinson B, Lake R (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490-4496
29. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73
30. Emens LA (2010) Chemoimmunotherapy. Cancer J 16:295-303
31. Zigler M, Villares GJ, Lev DC, Melnikova VO, Bar-Eli M (2008) Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 9:307-311
32. Jure-Kunkel MN, Masters G, Girit E, Dito G, Lee FY (2008) Antitumor activity of anti-CTLA-4 monoclonal antibody in combination with ixabepilone in preclinical tumor models. J Clin Oncol 26(May 20 suppl). Abstract 3048
33. Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW (2011) CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol 73:301-308
34. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120:1111-1124
35. Shurin GV, Tourkova IL, Kaneno R, Shurin MR (2009) Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183:137-144
36. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S, Berman D (2012) Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 35:89-97
37. Ariyan CE, Quezada S, Corse E, et al. (2011) Improved survival with gemcitabine and CTLA-4 blockade in a murine model of prostate cancer. Presented at 102nd annual meeting of the American association for cancer research, 2011 Apr 2-6, Orlando, FL. Philadelphia (PA), AACR Cancer Res 71(8 Suppl). Abstract 1786
38. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA (2013) Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 8(4):e61895
39. Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M (2012) CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 11:1809-1819
40. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2012 Aug 2 [Epub ahead of print]
41. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastrian M, Neal J, Lu H, Cuillerot JM, Reck M (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046-2054
42. Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD (2013) Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 13:7 2013 May 1 [Epub ahead of print]